Saroglitazar is being studied for its potential to target bile acid dysregulation and inflammation in primary biliary cholangitis (PBC). The treatment is part of a broader discussion on the evolving landscape of PBC treatment. Recent news updates have highlighted saroglitazar and other developments in the field of hepatology.